Abstract |
Cefoperazone is a broad-spectrum cephalosporin that has been used extensively to treat infections in cancer patients. A recent survey demonstrated only a 6% resistance to this drug among Gram-negative bacteria. The combination of cefoperazone plus sulbactam was studied in vitro against consecutive isolates causing bacteremia in cancer patients as well as those selected for resistance to cefoperazone. Both a fixed ratio of sulbactam/ cefoperazone (2:1 w/w) and selected concentrations of sulbactam (2, 4, 8, and 16 micrograms/ml) were studied. Sulbactam was shown to increase the susceptibility of various unselected Gram-negative bacilli; this effect increased with larger concentrations of sulbactam. The addition of sulbactam at optimum concentration levels made 29 of 65 cefoperazone-resistant Gram-negative bacilli susceptible. This effect was seen most markedly for Acinetobacter spp.
|
Authors | G P Bodey, P Miller, D H Ho |
Journal | Diagnostic microbiology and infectious disease
(Diagn Microbiol Infect Dis)
1989 Jul-Aug
Vol. 12
Issue 4 Suppl
Pg. 209S-214S
ISSN: 0732-8893 [Print] United States |
PMID | 2591178
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Bacterial Infections
(complications, drug therapy, microbiology)
- Cefoperazone
(administration & dosage)
- Drug Resistance, Microbial
- Drug Therapy, Combination
(administration & dosage)
- Gram-Negative Bacteria
(drug effects, isolation & purification)
- Humans
- In Vitro Techniques
- Neoplasms
(complications, microbiology)
- Sulbactam
(administration & dosage)
|